Related Experiment Video
Updated: May 13, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Fulminant Cardiac Sarcoidosis Successfully Treated With Aggressive Immunosuppressive Therapy
Kaori Yasumura1, Fusako Sera1, Yasuhiro Akazawa1
1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
Fulminant cardiac sarcoidosis, though rare, can mimic giant cell myocarditis. Aggressive immunosuppressive therapy, similar to that used for giant cell myocarditis, led to improved cardiac function and recovery in a patient requiring mechanical circulatory support.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Cardiac sarcoidosis typically presents with subacute symptoms, with fulminant cases requiring mechanical circulatory support being exceptionally rare.
- Differentiating cardiac sarcoidosis from giant cell myocarditis is challenging due to overlapping histopathological and clinical features.
Observation:
- A 55-year-old woman presented with acute heart failure, ventricular arrhythmias, and atrioventricular block, necessitating mechanical circulatory support including extracorporeal membrane oxygenation and Impella 5.0.
- Pathological examination revealed cardiac sarcoidosis with inflammatory cell infiltration, giant cells, fibrosis, and granulomas.
Findings:
- Despite the fulminant presentation, aggressive immunosuppressive therapy with corticosteroids and cyclosporine was initiated, considering the possibility of giant cell myocarditis.
- The patient demonstrated significant improvement in cardiac function, allowing for discontinuation of all mechanical circulatory support and inotropic agents.
Implications:
- Aggressive combination immunosuppressive therapy may offer a favorable outcome in fulminant cardiac sarcoidosis, even when indistinguishable from giant cell myocarditis initially.
- This case highlights the potential therapeutic benefits of early and intensive immunosuppression in severe cardiac inflammatory conditions.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Heart Failure Drugs: Inotropic Agents
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

